Nabeel Farooqui, MD
Allergy & Immunology · Fishers, INNPI 1174732804
Payments from drug & device makers
Across 1,828 payments — averaging $715.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$555K
- AstraZeneca$371K
- Teva Pharmaceuticals USA, Inc.$89K
- Regeneron Healthcare Solutions, Inc.$70K
- Sanofi$55K
- Optinose US, Inc.$51K
- plus $120K from 39 others
Across 1 payment — averaging $12,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$13K
What the payments were for
- Consulting fees$145,43812%
- Speaking & faculty fees$926,32276%
- Travel & lodging$101,0668%
- Food & beverage$37,9293%
- Education$1810%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$528,046
- DUPIXENT$116,389
- FASENRA$104,675
- AIRSUPRA$80,142
- TEZSPIRE$63,517
- Xhance$49,763
- XOLAIR$30,785
- ProAir Digihaler$28,039
- AirDuo RespiClick$23,333
- CINQAIR$23,049
- AirDuo Digihaler$19,774
- ArmonAir Digihaler$19,066
- AYVAKIT$16,790
- NEFFY$15,845
- Ryaltris$5,444
- Odactra$5,250
- Rhapsido$4,743
- PROAIR$4,660
- Rinvoq$2,300
- Hizentra$113
How this compares
$1,308,830 in reported general payments places this provider in the 95th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 15 | $617,699 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 57 | $396,626 |
| Dupixent PenDupilumab | 35 | $242,237 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 18 | $166,479 |
| XolairOmalizumab | 40 | $116,713 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $115,606 |
| NucalaMepolizumab | 31 | $115,142 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $81,785 |
| Dupixent SyringeDupilumab | 21 | $79,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $60,391 |
| TezspireTezepelumab-Ekko | 13 | $55,577 |
| HyqviaIgg/Hyaluronidase,recombinant | 15 | $45,231 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $15,610 |
| Epinephrine | 20 | $7,399 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 33 | $3,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $83 | $617,69915 claims |
| CSL BehringHizentra | $1,055 | $396,62657 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $554,719 | $191,143120 claims |
| PfizerPanzyga | $774 | $166,47918 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Hyqvia | $406 | $127,01627 claims |
| Bio Products Laboratory USA, Inc.Gammaplex | $156 | $115,60613 claims |
| AstraZenecaTezspire | $370,618 | $55,57713 claims |
| Hikma Pharmaceuticals USAEpinephrine | $5,673 | $7,39920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Fishers
- James HarrisSouth Bend$1.7M
- Majed KoleilatEvansville$713K
- Mitchell SmithGreenwood$425K
- Anne McLaughlinEvansville$380K
- David PattersonNoblesville$254K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Sohaib AleemSouth Bend$98K
- Pinkus GoldbergIndianapolis$89K
- Pooja PatelMerrillville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.